Background: BN80915 (diflomotecan) is an E-ring modified camptothecin analogue, which possesses greater lactone stability in plasma compared with other topoisomerase I inhibitors. This phase I study was carried out using a daily times five administration schedule (d·5) repeated three weekly. The primary objective was to determine the maximum tolerated dose (MTD) and recommended dose (RD) for phase II studies. Secondary objectives were to determine the safety and pharmacokinetic (PK) profile, and to make a preliminary assessment of antitumour activity.
introduction
The fluorinated homocamptothecin diflomotecan (BN80915) (R)(5-ethyl 9,10-difluoro-4,5,dihydro-5hydroxy-1H-oxepino [39,49:6,7] indolizino [1,2-b] quinoline-3,15[
13 H]dione) is a water insoluble topoisomerase I inhibitor [1, 2] (Figure 1 ). Homocamptothecins are camptothecin analogues bearing a 7-membered b-hydroxylactone ring, with enhanced lactone stability, in place of the naturally occurring 6-membered ahydroxylactone. Since a 1-carbon ring expansion is chemically termed a homoligation, these new lactone-or E-ring modified compounds were named homocamptothecins. As a result of the enhanced stability of the active form, homocamptothecins were anticipated to exert greater topoisomerase I inhibition and antitumour efficacy than the currently approved analogues such as irinotecan and topotecan (Hycamtin; GlaxoSmithKline, Philadelphia, PA). In a variety of preclinical models the homocamptothecins do exhibit greater potency than either of these agents. Animal toxicology studies were consistent with previous findings from cytotoxic agents.
Topoisomerase I inhibitors exert their antiproliferative activity during S phase of the cell cycle where drug-induced cleavable complexes result in the formation of double-stranded DNA breaks in sensitive cell lines [3, 4] . The biology of this event was consistent with the results of preclinical models where diflomotecan was most active when administered as multiple fractions [5] .
A previous phase I trial was carried out using an oral formulation of diflomotecan given once daily for 5 days every 3 weeks. As there was not a suitable oral formulation, the i.v. solution of diflomotecan was taken by mouth in that trial.
Toxicity was acceptable at the 0.27-mg/day oral dose level with only two out of 11 patients experiencing dose-limiting toxicity (DLT) (grade 4 neutropenia >7 days). Other toxic effects observed included anaemia, grade 3 thrombocytopenia, mucositis and fatigue [6] . It was not practical to further develop the i.v. drug for oral administration, in part because of its taste. It was, therefore, necessary to investigate additional i.v. schedules of diflomotecan until an acceptable oral formulation became available. As a result we carried out this phase I and pharmacokinetic (PK) study of diflomotecan employing a daily times five administration schedule (d·5), repeated three weekly.
The primary objective of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD). Secondary objectives were to determine the safety profile, the PK characteristics, PK/pharmacodynamic correlations and to make a preliminary assessment of antitumour activity.
patients and methods

eligibility criteria
Patients with cytologically or histologically confirmed diagnosis of a malignant solid tumour, either refractory to conventional chemotherapy or for whom no effective therapy existed were eligible. Other eligibility criteria included: age ‡18 years; World Health Organisation performance status zero to two; estimated life expectancy of ‡12 weeks; no previous anticancer therapy for at least 4 weeks (6 weeks for nitrosourea, mitomycin C or carboplatin) and adequate haematopoietic (absolute neutrophil count ‡1.5 · 10 9 /l, platelet count ‡100 · 10 9 /l and haemoglobin ‡10.0 g/dl), hepatic {serum total bilirubin <1.25 · the institutional upper normal limit [UNL, with serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) £2.5 · UNL or £5.0 · UNL in case of liver metastases]} and renal function (serum creatinine concentration £1.5 UNL or creatinine clearance >60 ml/min.). Prior systemic treatment, including investigational drugs, surgery or radiation therapy was acceptable provided it had been completed at least 4 weeks before study registration. Specific exclusion criteria included hypersensitivity to any of the test materials or related compounds, previous bone marrow transplantation, pregnant or lactating women, clinical evidence of serious intercurrent disease, active or uncontrolled infection, brain metastases or major organ failure. The Institutional Ethical Boards in Glasgow and Rotterdam approved the study protocol and patient information sheets with consent form. All patients gave written informed consent before study entry.
treatment
Ipsen Biotech (Paris, France) supplied diflomotecan for intravenous (i.v.) infusion in 4 ml amber glass vials containing 10 mg of the active ingredient dissolved in 0.5 g of dimethylacetamide. Diflomotecan solution was protected from light both immediately after reconstitution and during infusion.
Prophylactic domperidone or metoclopramide was permitted in the first cycle of treatment at the discretion of the investigator; in subsequent cycles there was no restriction on antiemetic prophylaxis. If nausea or vomiting occurred after treatment, therapeutic antiemetics were administered as clinically indicated. The prophylactic use of colony-stimulating factors was not permitted, but they could be given therapeutically at the discretion of the clinician. High-dose loperamide therapy was administered orally for diflomotecan-induced grade ‡2 diarrhoea, at a starting dose of 4 mg with the first episode of diarrhoea, then 2 mg every 2 h for at least 12 h. The patient stopped loperamide after a 12-h period free from diarrhoea. If the diarrhoea persisted for >6 h despite the recommended loperamide treatment, hospitalisation was recommended.
study design
The starting dose of diflomotecan was 0.05 mg/m 2 /day given as a 20-min infusion once daily for five consecutive days every 3 weeks. This was based both on preclinical data (being less than one-tenth the MTD of 1.475 mg/m 2 /day in rats), and experience in a previous dose escalation and bioavailability trial of oral diflomotecan using a 5-day oral administration schedule. This trial established an RD of 0.27 mg/day [6] , and mean oral bioavailability of 65% (range 7.6% to 100%). This is equivalent to a mean i.v. dose of 0.19 mg/day at the RD. Adjusting for body surface area, this equates to a mean daily dose of 0.11 mg/m 2 .
The dose of diflomotecan was escalated by between 10% and 100% depending on the nature and severity of toxicity at the prior dose level. Dose escalation ceased once the MTD had been identified. Up to 12 additional patients were then treated at the previous lower dose to confirm its tolerability as an RD for further studies. At least three patients were entered in all dose levels. If one of the three patients experienced DLT, three additional patients were entered at that dose level.
Dose-limiting toxic effects were identified during the first cycle only. These were defined as one of the following:
1. Grade 4 neutropenia lasting for ‡7 days. 2. Febrile neutropenia or neutropenic infection. 3. Thrombocytopenia <25 · 10 9 /l, or <50 · 10 9 /l with haemorrhage.
4. Any ‡ grade 3 non-haematological toxic effects attributable to the study drug (except untreated nausea, vomiting or diarrhoea). 5. Inability to complete repeated infusions of diflomotecan during cycle 1 as a consequence of drug-related toxicity.
The MTD was defined as that dose which induced DLT in no more than one-third of patients during their first cycle of treatment. The dose recommended for further development, or RD, was that immediately below the MTD. Toxic effects were defined according to the National Cancer Institute Common Toxicity Criteria (Version 2.0 1999) and judged dose limiting only if attributable to the study drug. Intrapatient dose escalation was not allowed. Treatment was repeated every 3 weeks, provided haematological and serum chemistry parameters had recovered to within the limits specified at study entry, and any other treatment-related toxic effects (with the exception of alopecia) had resolved to baseline (£grade 2) or levels permitted at study entry. If a patient experienced a DLT or other severe toxicity during treatment the dose for subsequent cycles was reduced to the previous dose level investigated. If treatment was delayed for >2 weeks the patient was withdrawn from the study. original article
Annals of Oncology treatment assessment
Before initiating therapy, a full medical history was taken and physical examination carried out. A complete blood cell (CBC) count, [including haemoglobin, white blood cell (WBC) with differential count, platelets, red blood cell] and serum biochemistry (including sodium, potassium, chloride, calcium, creatinine or creatinine clearance, glucose, total bilirubin, total protein, serum albumin, alkaline phosphatase, lactic dehydrogenase, AST, ALT and glutaryl transpeptidase), were carried out, as were tumour markers (if appropriate), urine analysis by dipstick, pregnancy test (in all females with reproductive potential), ECG and chest X-ray. Weekly evaluations included history, physical examination, toxicity assessment, haematology and biochemistry tests. Haematology tests were determined on day 1, twice weekly of each cycle, and daily if febrile neutropenia occurred. Serum biochemistry was determined weekly. Radiological tumour evaluation was assessed after every two cycles and the best response to diflomotecan expressed according to RECIST criteria [7] . All patients who received at least one infusion of diflomotecan were analysed for toxicity, and those who had at least one on-treatment tumour measurement were assessed for response.
sample collection and drug analysis The plasma concentrations of diflomotecan and its metabolite BN80942 were quantified by high-performance liquid chromatographytandem mass spectrometry-MS-MS after extraction from the matrix with acid diethyl ether as described previously [6] .
PK and pharmacodynamic data analysis PK parameters were calculated by standard noncompartmental methods using WinNonlin software (Scientific Consulting Inc.). The parameters determined for BN80915 and BN80942 included peak plasma concentration (C max ), elimination rate constant (k z ) estimated by linear regression of the terminal phase of the semilogarithmic plasma levels curve when this was clearly defined and elimination half-life (t ½,z ) using the equation: t ½,z = ln 2/k z . The area under the plasma concentration time curve (AUC) from time zero to the last experimental time point (AUC (0ÿt) ) was estimated by the linear-log trapezoidal rule and AUC (0ÿN) was calculated using the equation: AUC (0ÿN) = AUC (0ÿt) + (C t /k z ), where C t is the predicted concentration at the last sampling time plasma clearance was calculated using the equation: CL = D (dose)/AUC (0ÿN) . The area under the first moment curve from time zero to the last experimental time point (t) (AUMC (0ÿt) ) was estimated by the linear-log trapezoidal rule and the area under the first moment curve from time zero to infinity (AUMC (0ÿN) ) was estimated by adding the AUMC (0ÿt) value to the expression of the equation: The relationship between AUC and the resulting myelosuppression expressed as a percentage of maximum inhibition from baseline levels of haematological parameters obtained during the first cycle of administration was explored using the pharmacodynamic models simple E max and sigmoid E max according to the following mathematical equations, respectively: E = E max Á C=C + EC 50 and E = E max Á C c =C c + EC c 50 where E = effect, E max = maximum effect and fixed at 100: EC 50 = AUC required to produce 50% of the drug-induced maximal effect (percentage of maximum inhibition for the haematological parameters obtained during the first cycle of administration), C = AUC value, and c = shape parameter.
statistical analysis
The analysis of variance (ANOVA) of repeated measures was used to estimate residual variances in some PK parameters as well as to compare PK parameters for which full PK data were available at both day 1 and day 4 of administration. The intrapatient variability was expressed as the coefficient of variation (CV) in percentage terms and calculated by means of the expression CV (%) = 100 (e Vr ÿ1) ) and two patients were taken off study.
haematologic toxicity
Reversible neutropenia was the principal DLT. The severity of haematologic toxicity was dose dependent (Table 3 ). In total, three of the 13 patients treated at 0.125 mg/m 2 dose level, experienced dose-limiting grade 4 neutropenia and this was defined as the RD. All of these three patients were heavily pretreated, having received three or more lines of prior chemotherapy.
nonhaematologic toxicity
There were no grade 4 non-haematological toxic effects or DLTs (Table 4) . Gastrointestinal toxicity was generally mild and diarrhoea uncommon. Only one patient experienced grade 3 diarrhoea at the 0.15-mg/m 2 /day dose level, which lasted <24 h. Twelve patients experienced mucositis, mainly grade 1 or 2 in intensity. The patient who had grade 3 diarrhoea also experienced grade 3 mucositis. Fatigue was frequently observed, but usually only grade 1 or 2 and often related to disease progression or anaemia rather than treatment with diflomotecan; four patients experienced grade 3 fatigue associated with disease progression. Alopecia was seen in 14 of the 30 patients. A transient grade 3 rise in c-glutamyltransferase (GGT) was observed in four patients but resolved without intervention; subsequent cycles of treatment were administered and increases in GGT were again observed, but were not clinically significant. One patient treated at the 0.125-mg/m 2 /day dose level experienced a grade 3 erythematous, itchy, maculopapular skin rash over the torso and limbs judged secondary to diflomotecan, which resolved over a 2-week period with the use of emollients and mild topical steroid creams. The patient had, however, clinical disease progression with worsening liver biochemistry tests and subsequently withdrew from the study. original article Annals of Oncology had a partial response in liver metastases after six cycles of the FOLFIRI regimen). This was achieved after four cycles of treatment and confirmed by radiological reassessment after the sixth cycle of treatment. The patient requested to withdraw from the study at that point and remained well with no evidence of disease progression for a further 8 months. An additional eight patients had disease stabilisation for a median of 15 weeks, (range 7-24 weeks).
PKs and pharmacodynamics
PKs was evaluated in 29 patients; one patient at the 0.125-mg/m 2 /day level was not included due to difficulties in blood sampling. The mean [± standard deviation (SD)] PK parameters after the first and fourth dose administration in cycle 1 for all dose levels are shown in Table 5 . Figure 2 shows the mean (± SD) diflomotecan plasma concentration levels following i.v. administration for day 1 and day 4 of cycle 1 at all dose levels.
When the ANOVA of repeated measures test was carried out to compare the most relevant PK parameters, using data from patients obtained on both day 1 and day 4 of administration at different doses, no statistical differences could be evidenced in C max /D, AUC/D, CL, t 1/2,z , MRT, V z and V ss attributable to the administration day (day 1 or day 4) providing no indication of either time-dependent or dose-dependent kinetics. There was, however, wide variability obtained in the main PK parameters such as AUC and CL, with CV (%) ranging from 17.1% to 76.1% and 15.1% to 100%, respectively, across all dose levels including data at day 1 and day 4.
In order to explore the relationship between myelosuppression and diflomotecan exposure, the percentage maximum inhibition of neutrophil and platelet counts was correlated with AUC after i.v. administration of diflomotecan following the first cycle in all patients. A summary of mean ± SD data is given in Table 6 . At the RD 0.125 mg/m 2 /day, mean percentages of maximum inhibition for WBC, neutrophils and platelets were 57.1%, 63.1% and 46.0%, respectively.
The relationship between AUC and the percentage maximum inhibition for the haematological parameters obtained during the first cycle of administration was explored using simple E max and sigmoid E max models. The results are summarised in Table 7 in which the observed AUC values required to produce 50% of the drug-induced maximal effect using a sigmoid E max model were 27.88, 24.00 and 37.73 ng/h/ml for WBC, neutrophils and platelets, respectively. These results are consistent with those obtained from another phase I trial [6] in which diflomotecan was given as a solution orally daily for 5 days every 3 weeks where these values were 36.63, 29.58 and 52.47/ng/h/ml, respectively. discussion Topoisomerase I inhibitors are an increasingly important class of anticancer drugs, with irinotecan widely used as a single agent or in combination with a fluoropyrimidine in metastatic colorectal cancer and topotecan used in the second-line management of ovarian cancer. Both of these compounds, however, have limitations in terms of activity and toxicity. The active lactone form of the camptothecin derivative is unstable and this may explain the sometimes limited antitumour activity in humans. Diflomotecan is more potent in several in vitro models than either irinotecan or topotecan and this may, in part, be explained by the increased stability of its active lactone form over the topoisomerase I inhibitors currently in use.
This study shows that i.v. administration of diflomotecan over 5 days, repeated every 3 weeks is feasible in adults with advanced solid malignancies. In general the regimen was well tolerated, with myelosuppression being the main toxicity. At the RD of 0.125 mg/m 2 /day, four out of the 13 patients treated experienced grade 4 neutropenia at the first cycle, three of which constituted a DLT. Only one episode of febrile neutropenia was observed at this dose level.
As in the previous phase I study of oral diflomotecan, and in contrast to some other topoisomerase I inhibitors, gastrointestinal toxicity was mild. Diarrhoea was surprisingly uncommon and generally not clinically serious with only grade 2 diarrhoea, nausea and vomiting observed at the RD. This is in contrast to irinotecan where grade 3 or 4 diarrhoea may occur in up to 25% of patients [8] . Fatigue was frequently observed, but felt in many cases to be related to anaemia or tumour progression. Alopecia was seen in 14 out of the 30 patients treated. Transient grade 3 rises in GGT were frequent but settled without intervention, did not delay subsequent cycles of treatment and were not clinically significant. One patient at the RD experienced a grade 3 skin rash.
PK analysis showed that the most relevant PK parameters were neither time nor dose dependent. There was, however, a wide interpatient variability in the main PK parameters such as AUC and CL at all dose levels. This high interpatient variability in PKs has also been observed with other topoisomerase I inhibitors, irinotecan [9] and topotecan. Analysis of the relationship between the CBC and diflomotecan exposure demonstrated that at the RD, the mean percentages of maximum inhibition for WBC, neutrophils and platelets were 57.5%, 63.1% and 46.0%, respectively (Table 6) .
Antitumour activity was not the primary end point of this study and the patient population was, in general, heavily pretreated with over half the patients having cancers not predicted to respond to a topoisomerase I inhibitor. One of 2  3  2  3  2  3  2  3  2  3  2  3 Annals of Oncology original article the patients with metastatic colorectal cancer (who previously received combination treatment with irinotecan and 5-FU), however, achieved a partial response and a further 11 patients had disease stabilisation for between two and six cycles of treatment.
In conclusion, the MTD and the RD of diflomotecan administered according to d·5 repeated three weekly is 0.15 Table 5 . Figure 2. Mean ± standard deviation BN80915 plasma concentration levels following intravenous administration of BN80915 (all doses, day 1 and day 4).
original article Annals of Oncology and 0.125 mg/m 2 /day, respectively. Although interpatient PK variability was wide, in general treatment was well tolerated, the principal toxicity being reversible myelosuppression. Further studies of diflomotecan (BN80915), using this i.v. daily · 5 schedule, are warranted.
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